The Pancreas Center has collaborated with Roche – Genentech for our most recent clinical trial: MORPHEUS a Phase 1b/2 novel pancreatic cancer immunotherapy development platform.
The Pancreatic Center has collaborated with Roche – Genentech for our most recent clinical trial. Roche-Genetech is a biotechnology research corporation that created the study MORPHEUS, a Phase 1b/2 novel pancreatic cancer immunotherapy development platform.
MORPHEUS is a new and innovative approach that has not been done before in the clinical research of pancreatic cancer. Clinical evidence shows that the specific chemotherapy mechanisms of actions in this study may improve antitumor responses. When antitumors interaction with our immunotherapies drug selection, the strength of this relationship may help decrease the growth of cancer tumors and improve the patients’ survival. Consequently, patients are presented with a unique opportunity unlike any other pancreatic cancer treatment. Instead of only having one treatment regimen like most current trials, patients are offered FOUR different regimens. Also, because this study has the flexibility of creating more treatment regimens throughout the continuation of the study, once patients continue showing positive responses, more treatment regimens may become available as well.
From a research perspective, MORPHEUS will significantly enhance potential long-lasting clinical effects findings in a wide range of cancers. Future participants will be providing scientists with evidence needed to continue developing trustworthy approaches. For example, determining how patients respond to a given immunotherapy and what combination of immunotherapies and/or conventional therapies will be beneficial against each tumor type.
The launch of MORPEUS is a monumental accomplishment and The Pancreas Center is proud to have been the first to enroll a patient in this new platform.